We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00151203
Recruitment Status : Active, not recruiting
First Posted : September 8, 2005
Last Update Posted : February 14, 2017
Celgene Corporation
Information provided by (Responsible Party):
Weill Medical College of Cornell University